title: Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia.
abstract: Thirteen relapsed or refractory AML patients were treated with the FLA regimen. A complete remission was observed in 54% of cases but the median duration of remission was short (4 months). These results suggest that the FLA regimen is not able to induce a durable complete remission in the poor-risk AML patients.
authors.forename: D
authors.initials: D
authors.lastname: Russo
authors.forename: A
authors.initials: A
authors.lastname: Candoni
authors.forename: R
authors.initials: R
authors.lastname: Grattoni
authors.forename: A
authors.initials: A
authors.lastname: Bertone
authors.forename: F
authors.initials: F
authors.lastname: Zaja
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods; D012307:Risk Factors; D013997:Time Factors; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D003561:Cytarabine; D014740:Vidarabine; C024352:fludarabine